Skip to main content

An official website of the United States government

You have 2 new alerts

Q301--Cytopathology & Thyrosequence Testing Service

General Information

  • Contract Opportunity Type: Special Notice (Original)
  • Original Published Date: Dec 08, 2022 11:58 am EST
  • Original Response Date:
  • Inactive Policy: Manual
  • Original Inactive Date: Jan 07, 2023
  • Initiative:
    • None

Classification

  • Original Set Aside:
  • Product Service Code: Q301 - MEDICAL- LABORATORY TESTING
  • NAICS Code:
    • 621511 - Medical Laboratories
  • Place of Performance:

Description

NOTICE OF INTENT. The Department of Veterans Affairs, Network Contracting Office 2 intends to solicit and award a sole-source, firm-fixed-price, Indefinite Delivery Contract (with individual task orders issued for the annual ordering periods) with Cytopath Biopsy Lab, Inc. (760 Westchester Ave., Rye Brook, NY 10573-1341) in accordance with 41 U.S.C. § 1901, as implemented by FAR 13.106(b)(2)(i): Only one responsible source and no other supplies or services will satisfy agency requirements. The contract anticipated effective date is January 3, 2023, for one year with four option years. This contract is for Cytopathology & Thyrosequence Testing Service. Contractor shall provide for the New York Harbor Healthcare System at Brooklyn VA Medical Center, 800 Poly place, Brooklyn NY, 11209 approximately 180 tests per year. Patient samples obtained through fine needle aspirate (FNA) biopsies are collected for both cytopathology assessment and ThyroSeq® GC. Initially cytopathology assessment is conducted. If the sample is read out as benign, or non-diagnostic, the sample is not sent out for genetic analysis, however if it is read as Bethesda III, IV, or V, ThyroSeq® GC Next Generation gene sequencing is performed. ThyroSeq® Genomic Classifier (GC) test utilizes next-generation sequencing to analyze DNA and RNA of 112 thyroid-related genes for four main classes of molecular alterations, including mutations, gene fusions, copy number alterations, and gene expression alterations. The results are processed by a unique Genomic Classifier (GC) and reported as Positive or Negative. As we move forward with targeted therapies, samples which are Bethesda VI (papillary carcinoma), or other thyroid cancers will also be sent for further testing. The NAICS code is 621511 (Medical Laboratories) with a small business size standard of $36.5 Million. This is for informational purposes only and is not construed as a commitment by the Government. This is not a request for offers. A determination by the Government not to compete this procurement based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurements for this item. Point of Contact is Safa Shleiwet, Contracting Officer at safa.shleiwet@va.gov

Contact Information

Contracting Office Address

  • 113 HOLLAND AVE
  • ALBANY , NY 12208
  • USA

Primary Point of Contact

Secondary Point of Contact





History

  • Jan 07, 2023 11:58 pm ESTSpecial Notice (Original)